-
European Medicines Agency (EMA) Warns Xeljanz Increases Risk Of Pulmonary Embolism (PE) And Deep Vein Thrombosis (DVT)
Recommends That Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots As Well Aa In Patients Older Than 65 Years Of Age (Posted by Tom Lamb at DrugInjuryWatch.com)…
-
Patients Treated With Imbruvica Had Increased Rate Of Fatal Cardiac Events Compared To Conventional Chemotherapy
Cardiovascular Adverse Drug Reactions Often Occurred Soon After Administration Of Imbruvica, According To Recent Medical Study (Posted by Tom Lamb at DrugInjuryWatch.com) Patients treated with Imbruvica (ibrutinib) had an increased occurrence of…
-
Lemtrada Adverse Events May Occur More Frequently Than Previously Noted By Drug Safety Regulators And Researchers
Ten Deaths Identified As Being Most Probably Related To Lemtrada, With Six Of These Cases Not Previously Reported, According To New Study (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "Dear Healthcare Professional…
-
Alzheimer’s Drug Aricept Linked To Rhabdomyolysis, A Potentially Serious Muscle Condition
Is Rhabdomyolysis A Side Effect For Aricept, Only, Or For Other Cholinesterase Inhibitors, Also? (Posted by Tom Lamb at DrugInjuryWatch.com) Back in January 2015 Health Canada issued a postmarket surveillance warning about…
-
Pancreatic Cancer Associated With Use Of Diabetes Medicines In DPP-4 Inhibitor Drug Class
Increased Risk For Patients With Newly Diagnosed Type 2 Diabetes According To Recent Medical Research Study (Posted by Tom Lamb at DrugInjuryWatch.com) Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) diabetes medicines is associated…
